Aitziber Buqué

10.4k total citations · 3 hit papers
51 papers, 6.2k citations indexed

About

Aitziber Buqué is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Aitziber Buqué has authored 51 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Immunology, 29 papers in Oncology and 20 papers in Molecular Biology. Recurrent topics in Aitziber Buqué's work include Immunotherapy and Immune Responses (19 papers), Immune Cell Function and Interaction (14 papers) and Cancer Immunotherapy and Biomarkers (13 papers). Aitziber Buqué is often cited by papers focused on Immunotherapy and Immune Responses (19 papers), Immune Cell Function and Interaction (14 papers) and Cancer Immunotherapy and Biomarkers (13 papers). Aitziber Buqué collaborates with scholars based in United States, France and Spain. Aitziber Buqué's co-authors include Lorenzo Galluzzi, Guido Kroemer, Laurence Zitvogel, Oliver Kepp, Juliette Humeau, Norma Bloy, Giulia Petroni, Takahiro Yamazaki, Jitka Fučíková and Isabelle Cremer and has published in prestigious journals such as SHILAP Revista de lepidopterología, Nature reviews. Immunology and Nature Immunology.

In The Last Decade

Aitziber Buqué

49 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immunogenic cell death in cancer and infectious disease

2016 2.2k citations Lorenzo Galluzzi, Aitziber Buqué et al. Nature reviews. Immunology profile →
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

2015 1.1k citations Lorenzo Galluzzi, Aitziber Buqué et al. Cancer Cell profile →
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors

2020 932 citations Lorenzo Galluzzi, Juliette Humeau et al. Nature Reviews Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aitziber Buqué United States	25	3.3k	3.2k	1.7k	1.1k	978	51	6.2k
Jitka Fučíková Czechia	37	2.8k 0.9×	3.6k 1.1×	1.5k 0.9×	767 0.7×	637 0.7×	70	5.6k
Michel Obéid Switzerland	22	4.2k 1.3×	3.5k 1.1×	1.5k 0.9×	888 0.8×	1.1k 1.1×	41	7.4k
Antoine Tesnière France	20	3.2k 1.0×	4.7k 1.5×	2.1k 1.2×	1.1k 1.1×	651 0.7×	27	7.6k
Eyad Elkord United Kingdom	41	4.3k 1.3×	3.9k 1.2×	2.2k 1.3×	443 0.4×	1.1k 1.1×	126	7.7k
Michael Dougan United States	39	3.5k 1.1×	2.8k 0.9×	1.3k 0.7×	492 0.5×	488 0.5×	129	5.9k
Veena Kapoor United States	44	5.2k 1.6×	6.1k 1.9×	2.5k 1.4×	1.0k 0.9×	777 0.8×	96	10.4k
Thorsten Hagemann United Kingdom	31	3.3k 1.0×	3.2k 1.0×	2.4k 1.4×	486 0.4×	587 0.6×	56	7.0k
Tony Lahoutte Belgium	50	2.1k 0.6×	1.3k 0.4×	3.1k 1.8×	796 0.7×	518 0.5×	163	7.3k
Ferdy J. Lejeune Switzerland	44	3.3k 1.0×	3.2k 1.0×	2.6k 1.5×	435 0.4×	1.0k 1.0×	119	7.3k
Sebastian Kobold Germany	36	3.3k 1.0×	2.7k 0.8×	1.7k 1.0×	775 0.7×	353 0.4×	141	5.5k

Countries citing papers authored by Aitziber Buqué

Since Specialization

Citations

This map shows the geographic impact of Aitziber Buqué's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aitziber Buqué with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aitziber Buqué more than expected).

Fields of papers citing papers by Aitziber Buqué

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aitziber Buqué. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aitziber Buqué. The network helps show where Aitziber Buqué may publish in the future.

Co-authorship network of co-authors of Aitziber Buqué

This figure shows the co-authorship network connecting the top 25 collaborators of Aitziber Buqué. A scholar is included among the top collaborators of Aitziber Buqué based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aitziber Buqué. Aitziber Buqué is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Buqué, Aitziber, et al.. (2025). Novel metabolic routes to cancer immune evasion. Trends in cancer. 11(6). 493–495. 1 indexed citations

Galluzzi, Lorenzo, et al.. (2024). Targeting CDK2 to circumvent treatment resistance in HR+ breast cancer. Trends in Molecular Medicine. 31(6). 495–497. 1 indexed citations

Anderson, Kristin G., David A. Braun, Aitziber Buqué, et al.. (2023). Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies. Journal for ImmunoTherapy of Cancer. 11(6). e006533–e006533. 12 indexed citations

Jiménez‐Cortegana, Carlos, Vanessa Klapp, Norma Bloy, et al.. (2022). Cytofluorometric assessment of cell cycle progression in irradiated cells. Methods in cell biology. 172. 1–16. 1 indexed citations

Petroni, Giulia, Aitziber Buqué, Lisa M. Coussens, & Lorenzo Galluzzi. (2022). Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. Nature Reviews Drug Discovery. 21(6). 440–462. 97 indexed citations

Petroni, Giulia, Aitziber Buqué, Takahiro Yamazaki, et al.. (2021). Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer. Clinical Cancer Research. 27(7). 1855–1863. 36 indexed citations

Sato, Ai, Aitziber Buqué, Takahiro Yamazaki, et al.. (2021). Immunofluorescence microscopy-based assessment of cytosolic DNA accumulation in mammalian cells. STAR Protocols. 2(2). 100488–100488. 8 indexed citations

Yamazaki, Takahiro, Alexander Kirchmair, Ai Sato, et al.. (2020). Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy. Nature Immunology. 21(10). 1160–1171. 234 indexed citations

Galluzzi, Lorenzo, Juliette Humeau, Aitziber Buqué, Laurence Zitvogel, & Guido Kroemer. (2020). Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nature Reviews Clinical Oncology. 17(12). 725–741. 932 indexed citations breakdown →

10.

Yamazaki, Takahiro, Aitziber Buqué, Marissa Rybstein, et al.. (2019). Methods to Detect Immunogenic Cell Death In Vivo. Methods in molecular biology. 2055. 433–452. 8 indexed citations

11.

Baracco, Elisa Elena, Federico Pietrocola, Aitziber Buqué, et al.. (2016). Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer. OncoImmunology. 5(6). e1139275–e1139275. 18 indexed citations

12.

Galluzzi, Lorenzo, Aitziber Buqué, Oliver Kepp, Laurence Zitvogel, & Guido Kroemer. (2016). The complement system is also important in immunogenic cell death. Nature reviews. Immunology. 17(2). 143–143. 9 indexed citations

13.

Vacchelli, Erika, Norma Bloy, Fernando Aranda, et al.. (2016). Trial Watch: Immunotherapy plus radiation therapy for oncological indications. OncoImmunology. 5(9). e1214790–e1214790. 67 indexed citations

14.

Bloy, Norma, Aitziber Buqué, Fernando Aranda, et al.. (2015). Trial watch: Naked and vectored DNA-based anticancer vaccines. OncoImmunology. 4(5). e1026531–e1026531. 32 indexed citations

15.

Vacchelli, Erika, Fernando Aranda, Norma Bloy, et al.. (2015). Trial Watch—Immunostimulation with cytokines in cancer therapy. OncoImmunology. 5(2). e1115942–e1115942. 44 indexed citations

16.

Amo, Laura, et al.. (2015). Podocalyxin-like protein 1 functions as an immunomodulatory molecule in breast cancer cells. Cancer Letters. 368(1). 26–35. 19 indexed citations

17.

Galluzzi, Lorenzo, Aitziber Buqué, Oliver Kepp, Laurence Zitvogel, & Guido Kroemer. (2015). Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell. 28(6). 690–714. 1141 indexed citations breakdown →

18.

Kepp, Oliver, Michaëla Semeraro, José Manuel Bravo‐San Pedro, et al.. (2015). eIF2α phosphorylation as a biomarker of immunogenic cell death. Seminars in Cancer Biology. 33. 86–92. 95 indexed citations

19.

Iribarren, Kristina, Norma Bloy, Aitziber Buqué, et al.. (2015). Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. OncoImmunology. 5(3). e1088631–e1088631. 108 indexed citations

20.

Buqué, Aitziber, et al.. (2012). Molecular mechanism implicated in Pemetrexed-induced apoptosis in human melanoma cells. Molecular Cancer. 11(1). 25–25. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact